All In Biotech

Drug Trial Radar · NCT02973672

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Jan 2016

Primary completion

Apr 15, 2019

Study completion May 2019

Sponsor

Lead sponsor
SurgimabIndustry
Sponsor type
Industry
Collaborators
Centre for Human Drug Research, Netherlands; Leiden University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis Eindhoven
First posted
Nov 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.

Conditions

  • Colon Cancer
  • Rectum Cancer
  • Pancreas Cancer
  • Metastatic Colorectal Cancer
  • Recurrent Colorectal Carcinoma

Interventions

  • SGM-101Drug

    4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-related adverse eventsTime frame: up to 10 days after the surgery

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Catharina Ziekenhuis Eindhoven

    Eindhoven, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Erasmus Medical Center Cancer Institute

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.